Clinical Trial

To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated May 17, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase I open, multi-center, first-in-human study evaluating JSKN016 in subjects with advanced metastatic solid tumors, divided into dose escalation and dose extension.
Trial Details
NCT Number NCT06592417
Lead Sponsor Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Conditions Advanced Malignant Solid Tumor
Enrollment 140 participants
Start Date 2024-04-30
Primary Completion 2026-05-17 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-09-19